12:00 AM
 | 
Jun 03, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Algeta, Bayer sales and marketing update

Algeta and Bayer launched Xofigo radium-223 dichloride (formerly Alpharadin) in the U.S. to treat castration-resistant prostate cancer (CRPC) in patients with symptomatic bone metastases. FDA approved Xofigo,...

Read the full 133 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >